To discuss the role of pharmacokinetic modeling in addressing gaps in drug use during pregnancy and its implications for dosing and research.
Key Findings:
Limited clinical data for pregnant women leads to uncertainty in treatment decisions.
Physiological changes during pregnancy significantly affect drug metabolism and response.
There are critical gaps in understanding drug transporters and UGT enzymes during pregnancy.
Clear communication can enhance willingness among pregnant women to participate in clinical research.
Interpretation:
Pharmacokinetic modeling is essential for improving drug safety and efficacy in pregnant populations by filling data gaps and informing clinical decisions.
Limitations:
Current models may not fully account for all physiological changes during pregnancy.
Data on certain drug metabolism pathways remains insufficient.
Conclusion:
Advancing simulation approaches can significantly improve drug development and dosing for pregnant women, addressing a critical gap in clinical research.
